EU's IMI details new research projects
The EU's Innovative Medicines Initiative announced details on its third wave of research projects that were launched in January with a total budget of EUR 215 million ($266.9 million) across five years. The projects include two coordinated by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK): model-based preclinical development of anti-tuberculosis (TB) drug combinations ( PreDiCT-TB); and development of tools to predict immune response to biopharmaceuticals ( ABIRISK). Sanofi (Euronext:SAN; NYSE:SNY) is coordinating the DIRECT project to research patient stratification for personalized Type II diabetes treatments. The University of Surray and Novartis AG (NYSE:NVS; SIX:NOVN) are working on a project to develop biomarkers for enhanced vaccine immunosafety ( BIOVACSAFE). ...